Our Pipeline
Innovative Dermatology Products
Advancing the science of cutaneous medicine to address unmet dermatological needs.
Our Product Portfolio
A diverse range of therapeutic candidates designed to improve patient outcomes in dermatology.
QTI-180935 (Phase 2): A small molecule JAK1/TYK2 inhibitor new chemical entity under development as a topical formulation for treatment of Atopic Dermatitis
QTI-105795 (Phase 2): A small molecule thyromimetic new chemical entity under development as a topical formulation for treatment of Androgenetic Alopecia
QTI-181064 (IND-ready): A small molecule prodrug JAK1/TYK2 inhibitor new chemical entity under development as a oral tablet for treatment of a variety of immunologic indications
What Sets Our Products Apart
Science-Driven. Patient-Focused.
Quetyx Therapeutics leverages deep expertise to create dermatological therapies that are innovative, effective, and safe.
New Chemical Entities
We develop unique new chemical entities to address dermatologic needs.
Clinical Validation
Multiple candidates have achieved Proof-of-Concept milestones in clinical studies.
Unmet Needs
Our pipeline targets conditions with significant gaps in current treatment options.
Ready to Learn More?
Explore the Science Behind Our Innovations
See how our research drives the next generation of dermatology solutions.